SLC5A2 and diabetes mellitus: At present, several sodium-glucose cotransporter 2 (SGLT2) inhibitors, which were initially developed as glucose-lowering agents for type 2 diabetes, have been shown promising benefits to reduce the risk of hospitalization for HF (HHF) and cardiovascular death regardless of the presence or absence of diabetes (8, 9).